MINNEAPOLIS, July 02, 2024 (GLOBE NEWSWIRE) — Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire) will release financial results for the second quarter 2024 after the close of trading on Tuesday, August 6. Inspire’s management team will host a corresponding conference call beginning at 5:00 p.m. Eastern Time to discuss the financial results and recent business developments.
A webcast of the call will be accessible via the Investor Relations page of the Inspire website or through this link: Inspire’s Q2 2024 earnings call webcast. For those not planning to ask a question of management, the Company recommends listening via the webcast.
If you plan to ask a question, please use the following link: Inspire’s Q2 2024 earnings call. After registering, an email will be sent, including dial-in details and a unique conference call access code required to join the live call. To ensure you are connected prior to the beginning of the call, the Company suggests registering a minimum of 10 minutes before the start of the call.
Following the call, a replay will be available on the Company’s Investor Relations website approximately two hours after the event and archived on the site for two weeks.
About Inspire Medical Systems
Inspire is a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea. Inspire’s proprietary Inspire therapy is the first and only FDA-approved neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea.
For additional information about Inspire, please visit www.inspiresleep.com.
Investor and Media Contact
Ezgi Yagci
Vice President, Investor Relations
ezgiyagci@inspiresleep.com
617-549-2443
In the newly-released educational guide What Is Rapé?, Sacred Connection covers essential topics around Rapé…
Accelerating platform-driven clinical innovation across vascular, neurovascular, and cardiovascular applications through a centralized Bionanomatrix™ IP…
Fourth Quarter 2025 Revenue of $1.45 to $1.48 Million, representing growth of ~90% year over…
SAN JOSE, CA / ACCESS Newswire / February 5, 2026 / VSEE Health, Inc. (NASDAQ:VSEE),…
Cellular findings show Telomir-Zn modulates intracellular metal balance linked to oxidative stress, mitochondrial dysfunction, DNA…
ESTERO, FL / ACCESS Newswire / February 5, 2026 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP)…